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Clinical Gastroenterology and Hepatology 2017;15:1742–1749Agreement Between Home-Based Measurement of Stool
Calprotectin and ELISA Results for Monitoring Inflammatory
Bowel Disease ActivityAnke Heida,* Mariska Knol,* Anneke Muller Kobold,‡ Josette Bootsman,* Gerard Dijkstra,§
and Patrick F. van Rheenen*
*Department of Paediatric Gastroenterology, Hepatology and Nutrition, University of Groningen, University Medical Centre
Groningen, Groningen, the Netherlands; ‡Department of Laboratory Medicine, University of Groningen, University Medical
Center Groningen, Groningen, the Netherlands; §Department of Gastroenterology, Hepatology and Nutrition, University of
Groningen, University Medical Center Groningen, Groningen, the NetherlandsBACKGROUND & AIMS: An increasing number of physicians use repeated measurements of stool calprotectin to
monitor intestinal inﬂammation in patients with inﬂammatory bowel diseases (IBDs). A lateral
ﬂow-based rapid test allows patients to measure their own stool calprotectin values at home.
The test comes with a software application (IBDoc; Bühlmann Laboratories AG, Schönenbuch,
Switzerland) that turns a smartphone camera into a results reader. We compared results from
this method with those from the hospital-based reader (Quantum Blue; Bühlmann Laboratories
AG) and enzyme-linked immunosorbent assay (ELISA) analysis.METHODS: In a single-center comparison study, we asked 101 participants (10 years of age or older) in the
Netherlands to perform the IBDoc measurement on stool samples collected at home, from June
2015 to October 2016. Participants then sent the residual extraction ﬂuid and a fresh specimen
from the same bowel movement to our pediatric and adult IBD center at the University Medical
Center Groningen, where the level of calprotectin was measured by the Quantum Blue reader
and ELISA analysis, respectively. The primary outcome was the agreement of results between
IBDoc and the Quantum Blue and ELISA analyses, determined by Bland-Altman plot analysis.RESULTS: We received 152 IBDoc results, 138 samples of residual extraction ﬂuid for Quantum Blue
analysis, and 170 fresh stool samples for ELISA analysis. Spearman’s rank correlation coefﬁ-
cient was 0.94 for results obtained by IBDoc vs Quantum Blue and 0.85 for results obtained by
IBDoc vs ELISA. At the low range of calprotectin level (<500 mg/g), 91% of IBDoc–Quantum Blue
results were within the predeﬁned limits of agreement (–100 mg/g), and 71% of IBDoc–ELISA
results were in agreement. At the high range of calprotectin level (‡500 mg/g), 81% of IBDoc–
Quantum Blue results were within the predeﬁned limits of agreement (–200 mg/g) and 64% of
IBDoc–ELISA results were in agreement.CONCLUSIONS: Measurements of fecal levels of calprotectin made with home-based lateral ﬂowmethod were in
agreement with measurements made by Quantum Blue and ELISA, as long as concentrations
were <500 mg/g. For patients with concentrations of fecal calprotectin above this level, ﬁndings
from IBDoc should be conﬁrmed by another method. (Netherlands Trial Registration Number:
NTR5133).Keywords: Biomarker; Telemedicine; Point-of-care test; Monitoring IBD Activity.Abbreviations used in this paper: CI, conﬁdence interval; ELISA, enzyme-
linked immunosorbent assay; FC, fecal calprotectin; IBD, inﬂammatory
bowel disease.
Most current article
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1542-3565
http://dx.doi.org/10.1016/j.cgh.2017.06.007Crohn’s disease and ulcerative colitis are progres-sive inﬂammatory bowel diseases (IBDs) that may
result in irreversible bowel damage. The ultimate goal of
treating IBD patients is to achieve symptom control and
stop disease progression to change the natural course of
the disease. The desired treatment target is mucosal
healing and fecal calprotectin (FC) levels correlate well
with this target.1–4 Asymptomatic patients whose FC
November 2017 Stool Calprotectin Home Test 1743levels drift away from the target range have an increased
risk to develop a disease ﬂare in the next 2–3 months,
while repeated FC levels in the normal range suggest
sustained remission.5
For 8 years we have been following children with
IBDs by periodically measuring calprotectin levels in
their sent-in stool samples with an enzyme-linked
immunosorbent assay (ELISA). Although there is little
agreement among IBD experts about the optimal cutoff
points for calprotectin, in children we considered levels
below 250 mg/g as indicative for disease remission
(green),6 levels above 500 mg/g as indicative for disease
ﬂare (red), and levels between 250 and 500 mg/g pro-
vided little guidance and required short-term retesting
(orange). Both physicians and patients found repeated
testing of calprotectin and the trafﬁc light color coding
helpful to guide therapy, but ELISA testing is time
consuming and requires a high level of expertise to
perform.7 Point-of-care calprotectin tests, including the
Quantum Blue lateral ﬂow immunoassay (Bühlmann
Laboratories AG, Schönenbuch, Switzerland), are less
time consuming, but patients are still forced to send or
bring a stool sample to the hospital.8 Bühlmann Labo-
ratories AG recently developed a lateral ﬂow–based
calprotectin test and a software application (IBDoc) that
turns an ordinary smartphone camera into a reader for
quantitative measurements at home. The software
application enables patients to perform a measurement
and receive the result without delay, provided that
there is an Internet connection available. We aimed to
compare this newmethod with the hospital-based lateral
ﬂow reader Quantum Blue and the established
ELISA method to see whether these tests agreed sufﬁ-
ciently for the new test to replace the old, or to use the 3
interchangeably.
Methods
This study was a single-center prospective study,
performed at the pediatric and adult IBD center at the
University Medical Center Groningen (Groningen, the
Netherlands).
Participants
Eligible participants were 10 years or older with good
knowledge of the Dutch language who had a smartphone
that was validated to run the IBDoc application
(Supplementary Table 1) and did not have an ileostomy.
We contacted candidate participants by telephone before
their next planned visit to the outpatient clinic. When
patients were interested in participation, we explained
the procedure during the same telephone conversation.
We then sent a study package including a pictorial al-
gorithm of the procedural steps, including instructions
for sample extraction and measurement, to the patient’s
home.Stool Collection and Sampling
Participants defecated onto a stool collection sheet
(included in the IBDoc package) held above the toilet
water and collected 2 samples from the same bowel
movement. The ﬁrst sample was collected with the
classical screw top container with spatula for ELISA
measurement at the hospital laboratory. The second
sample was taken with a CALEX valve extraction device
(Bühlmann Laboratories AG) (Figure 1).
After performing the home test, both the CALEX valve
extraction device and the screw-top container were sent
in a resealable biomaterial envelope to the Department
of Laboratory Medicine of the University Medical Center
Groningen.Calprotectin Measurements
The level of calprotectin was measured 3 times
(Figure 2). First, patients used the IBDoc application on
their smartphone to read the FC level in the CALEX
extraction device, using a lateral ﬂow technique. To do so
they had to place the camera above the cassette and a
picture was automatically taken. The image was then
analyzed and the quantitative calprotectin result was
directly shown on the screen (an instruction video of the
step-by-step procedure can be found at www.ibdoc.net). At
the same time the research team received a notiﬁcation that
an IBDocmeasurement was performedwith a direct link to
this result on a secured web portal. Second, one experi-
enced laboratory technician in the University Medical
Center Groningen, who was blinded for IBDoc results, used
the Quantum Blue Extended Reader (Bühlmann Labora-
tories AG) to read the FC level in the send in CALEX
extraction device, also with a lateral ﬂow technique.9 Third,
the fresh stool sample was extracted in the hospital labo-
ratory and the FC level was measured with the ELISA
technique. The fresh samples were manually weighted and
stored at –20C until analysis. The stool samples were then
thawed for calprotectinmeasurementswith the fCALELISA
(Bühlmann Laboratories AG) on a Dynex DS2 Automated
ELISA system (Alpha Labs, Easleigh, UK). The IBDoc and
Quantum Blue tests covered a measurable range of cal-
protectin from 30 to 1000 mg/g, and the ELISA tests
covered a range of 40 mg/g and above. For the analyses we
therefore registered calprotectin values below 40 mg/g as
40 mg/g and values above 1000 mg/g as 1000 mg/g.Outcome Measures
The primary outcome was the agreement of results
between IBDoc and the clinically accepted ELISA method,
using Bland-Altman plot analysis. First, we reasoned that
disagreement in the lower range of the test (ie, between 40
and 500 mg/g) could lead more easily to misinterpretation
of disease activity than disagreement in the higher range
(>500 mg/g). We therefore used predeﬁned acceptable
Figure 1. IBDoc sampling and measurement. Adapted with permission from Bühlmann Laboratories AG.23
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for the lower range, and 200 mg/g for the higher range.
Second, we assessed concordance of ELISA and IBDoc
readings in each of the 3 FC ranges used in our clinical
practice (ie, <250 mg/g, 250–500 mg/g, and >500 mg/g).
As there is currently no consensus among IBD experts
about the range of FC associated with mucosal healing, we
also reported concordance of ELISA and IBDoc readings for
other frequently used dichotomous cutoffs (namely 50,
150, 200, 250, and 300 mg/g). Other outcome measures
included agreement between patient-performed IBDoc
measurements and hospital-based Quantum Blue mea-
surements of the same extract, and an evaluation of the
usability of the IBDoc method by patients.
Quality Measurement of Scanning Methods
Prior to the study, we veriﬁed the quality of the
scanning methods of both the IBDoc application on an
iPhone 4S and the Quantum Blue Extended reader, as
described in the Supplementary Methods and Results
and Supplementary Table 2.
Sample Size Calculation
We aimed to include at least 100 paired samples
in the lower range of the test (ie, between 40 and500 mg/g). This sample size was based on the recom-
mendation of Bland.10
Statistical Analysis
Data were recorded electronically by using SPSS
version 23.0 for Windows (IBM Corporation, Armonk,
NY). Agreement between IBDoc and ELISA results, and
between IBDoc and Quantum Blue results was compared
with a Bland-Altman plot.11 The Bland-Altman plot as-
signs the average of the old and new method on the
x axis, and the difference between both on the y axis.
Furthermore, we calculated the Passing-Bablok regres-
sion coefﬁcient and Spearman rank correlations coefﬁ-
cient. Concordance of IBDoc and ELISA readings in each
of the 3 FC ranges used in our clinical practice were
presented in a scatterplot. Graphs were constructed with
GraphPad Prism, version 5.04 for Windows (GraphPad
Software, San Diego, CA). A P value below .05 was
signiﬁcant.
Ethical Considerations
This studywas performed according to the Declaration
of Helsinki. The Medical Ethical Committee of the
University Medical Center in Groningen decided that a
study measuring markers in voluntary stool samples did
Figure 2. Study ﬂow indicating 3 calprotectin measurements
from the same bowel movement. ELISA, enzyme-linked
immunosorbent assay.








- Children (<18 y of
age)
19 58 40 (40–198)
- Adults (18 y of
age)
82 94 195 (69–588)
Disease activity during stool samplingb
- Symptomatic
disease
Not applicable 50 445 (199–1010)
- Asymptomatic
disease
Not applicable 84 47 (40–150)
- Unknown Not applicable 18 420 (89–713)
IQR, interquartile range.
aMeasured with enzyme-linked immunosorbent assay.
bDisease activity, as assessed by the Physician’s Global Assessment, was
reported when the interval between stool sampling and face-to-face encounter
with the doctor was shorter than 1 month.
November 2017 Stool Calprotectin Home Test 1745not require approval according to the Dutch Medical
Research Involving Human Subjects Act. All adult partic-
ipants, legal guardians from pediatric participants, and
children 12 years of age and older gave informed consent
to use data generated by routine medical care. The data
were collected and recorded by the investigators in such a
manner that subjects could not be identiﬁed, directly or
through identiﬁers linked to the subjects. This study was
conducted in compliance with the Clinical Trial Agree-
ment, the study protocol, designated Standard Operating
Procedures and the international standard for clinical
studies of medical devices (ISO 14155: 2011 Clinical
investigation of medical devices for human subjects –
Good Clinical Practice). All authors had access to the study
data and reviewed and approved the ﬁnal manuscript.Results
Between June 2015 and October 2016, 306 random
patients with IBD were approached by telephone, of
which 211 were willing to participate. Sixty of them did
not have access to a validated smartphone and were
excluded from participation. The remaining 151 patients
received a study package. In the end 101 patients
actively participated and sampled 170 bowel movements
(Figure 2). Median age of the participants was 24 (range,
10–59) years (Table 1). A total of 152 IBDoc results were
transmitted to the secured web portal. Eighteen attempts
to measure and transmit an IBDoc measurement failed
for various reasons, including application dysfunction,
slow adjustment of focus when scanning the test
cassette, or being too much in a hurry to await the test
result. The hospital laboratory received 138 CALEX valve
extraction devices and 170 screw-top containers. Median
transport time was 2 (range, 0–7) days, and 82% of
samples arrived in the hospital laboratory within
72 hours after collection (Supplementary Figure 1).
IBDoc vs ELISA
We compared IBDoc and ELISA measurements in 152
paired samples. In Figure 3A we present a Bland-Altman
plot with 124 measurements situated in the lower cal-
protectin range (500 mg/g) and 28 measurements in
the higher calprotectin range (>500 mg/g). We found
81% (100 of 124) and 64% (18 of 28) of IBDoc mea-
surements were within predeﬁned limits of agreement in
respectively the lower and higher calprotectin range. The
mean difference (IBDoc minus ELISA) was –1.7 mg/g in
the lower range and –52 mg/g in the higher range.
Passing-Bablock regression analysis showed a slope
of 0.80 (95% conﬁdence interval (CI), 0.72–0.88) with an
Figure 3. Bland-Altman
plot showing difference




IBDoc and Quantum Blue
measurements. The pink
zone corresponds with our
predeﬁned limits of agree-
ment, which were arbitrary
set at 100 mg/g for the
lower calprotectin range,
and 200 mg/g for the
higher range. The outer
lines correspond with the
95% limits of agreement
(SD, 1.96).
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Spearman’s rank correlation coefﬁcient was 0.85
(P < .001).
The concordance between IBDoc and ELISA readings
in each of the 3 FC ranges used in our clinical practice is
presented in Figure 4. A total of 108 of 152 test pairs
(71%) were concordant. Discordant test pairs leading to
overt misinterpretation of disease activity (ie, calpro-
tectin >500 mg/g with one method and <250 mg/g with
the other) were observed in 6 of 152 stool samples (4%).
Two of 6 discordant test pairs, depicted in the right
lower corner of Figure 4, were caused by 1 participant
who did not observe the advised incubation time. As a
consequence, detachment of fecal material from the
sampling grooves was incomplete. Stool consistency,
transport time, age of participant (adult or child), andtype of smartphone were not clearly related to discor-
dant results (data not shown). The concordance between
IBDoc and ELISA reading for other frequently
used dichotomous cutoff values is presented in
Supplementary Table 3.IBDoc vs Quantum Blue
We compared patient-performed IBDoc smartphone
readings and Quantum Blue readings by laboratory staff
in 138 pairs of the same extraction ﬂuid and show the
corresponding Bland-Altman plot in Figure 3B. In the
lower calprotectin range 95 of 104 (91%) IBDoc readings
were within predeﬁned limits of agreement, and in the
higher ranges 24 of 34 IBDoc results (71%). The mean
Figure 4. Scatterplot showing calprotectin readings with IBDoc against enzyme-linked immunosorbent assay (ELISA) method.
Concordance is deﬁned as calprotectin levels in the same category (<250, 250–500, >500 mg/g) for both IBDoc and ELISA.
November 2017 Stool Calprotectin Home Test 1747difference (IBDoc minus Quantum Blue) was –16 ug/g in
the lower range and –84 ug/g in the higher range.
Passing-Bablock regression analysis showed a slope of
0.85 (95% CI, 0.79–0.91) with an intercept of 12 (95%
CI, 16–40) and R2 of 0.84. Spearman’s rank correlation
coefﬁcient was 0.94 (P < .001).Self-Reported Usability
Sixty-three participants returned the questionnaire
about the usability of the home test (response rate,
62%). A total of 87% of the respondents were of the
opinion that the test was not difﬁcult to perform. Holdingthe smartphone in the right position to scan the test
cassette was perceived as the most difﬁcult step in the
home test, and 97% of the respondents were interested
in using the home test in the future.
Discussion
Summary of Main Findings
The results show that the majority of calprotectin
measurements performed at home with a lateral ﬂow
immunoassay and smartphone reader agreed sufﬁciently
with the ELISA-based quantiﬁcation of calprotectin in the
1748 Heida et al Clinical Gastroenterology and Hepatology Vol. 15, No. 11hospital laboratory, provided that calprotectin levels are
below 500 mg/g. In the higher calprotectin range a sub-
stantial proportion of pairs exceeded the predeﬁned
limits of agreement (200 mg/g). Furthermore, we
showed that the smartphone reader used by patients at
home performed as good as the point-of-care Quantum
Blue reader in the hospital.
Additional beneﬁts of the home test include a
reduction of the burden on hospital laboratory resources
and a more patient-friendly sampling technique (with a
pin instead of a spatula).12Comparisons With Existing Literature
To the best of our knowledge, this is the ﬁrst study
that compared the performance of the FC home test with
both a point-of care test (Quantum Blue) using the same
extraction ﬂuid and the ELISA test.
In 2010 a Danish research team ﬁrst described the
use of a lateral ﬂow device that could be read by a
tabletop scanner connected to a computer with special
software (CALPRO Inc, Oslo, Norway).13 In the same
paper it was shown that the lateral ﬂow device could also
be analyzed by taking a picture with a mobile phone and
sending it to a server for evaluation. Both methods
showed acceptable agreement compared with ELISA, but
in this study the tests were carried out by an experienced
laboratory technician who used the same extracted
sample for all 3 methods. The same group recently re-
ported the results of a study comparing long distance
reading of a lateral ﬂow technique from a different
manufacturer (CalproSmart, Calpro AS, Lysaker, Norway)
with ELISA.14 They found a signiﬁcant but lower
Spearman rank correlation compared with our IBDoc
results (r ¼ 0.67 vs r ¼ 0.85). The reader used in this
study covered a measurable range of calprotectin from
30 to 600 mg/g, and as a consequence of this smaller
range the maximum difference that could be measured
between the lateral ﬂow test and ELISA was 570 mg/g,
compared with 960 mg/g in our study. Major disadvan-
tage in the Danish study included the use of a single type
of smartphone for standardization purposes, whereas
we included measurements from 16 different types of
validated smartphones.Limitations of the Study
There are some limitations in our study that need to
be addressed. First, the study participants were patients
with a suitable smartphone and interest in home testing,
rather than random IBD patients. We might have
included a sample of patients with higher socioeconomic
status and better education than others. Second, we
observed a median delay of 2 days between IBDoc home
testing and arrival of stool in our hospital, which could
have inﬂuenced the agreement between the results. A
recent study on the stability of calprotectin in fresh stoolshowed no signiﬁcant difference in concentrations be-
tween samples kept at room temperature for 1–3 days,
but between 3 and 7 days a mean decrease of 28% was
found.15 In our study 82% of fresh stool samples arrived
at the hospital laboratory within 3 days, and none more
than 7 days after collection. With the introduction of
home extraction and reading potential degradation of
calprotectin in send in stool samples will no longer be an
issue of importance.
Implications for Clinical Practice
The evidence base for repeated FC testing in asymp-
tomatic patients aimed at early recognition of disease
exacerbation is accumulating.5 Simultaneously, the
number of telemonitoring initiatives for IBD care is ris-
ing.16–19 Calprotectin home monitoring with a smart-
phone ﬁts perfectly in the current spirit of the times and
is another important step toward patient-centered
care.20 Whether FC home testing is cost effective
should be evaluated in future studies. The actual price
for IBDoc tests is approximately V30, compared with
approximately V41 per ELISA test (which includes labor
and equipment costs).
When repeated calprotectin home testing is imple-
mented it is important to realize that the total variation
between successive measurements can be inﬂuenced by
biological variation (ﬂuctuations within same subject),
preanalytical variation (differences in collection tech-
nique, transport, storage, and handling of stool), and
analytical variation (differences in precision of assay). In
our study, taking too little time for the extraction process
explained 2 of 6 discordant test pairs. Technical
competence is not only an important element of training
for hospital based laboratory technicians, but also for
patients who wish to use a point-of-care calprotectin test
at home. We therefore recommend to train interested
patients in a skills lab until proﬁciency criteria have been
met.21Conclusions
We found sufﬁcient agreement between the home-
used lateral ﬂow test and the hospital-based ELISA test
in the lower ranges of calprotectin to use this new test
for telemonitoring of patients with asymptomatic IBD. In
line with recent literature about FC monitoring, we
suggest that conﬁrmation of elevated IBDoc readings is
done before therapy adjustment is considered.1,22Supplementary Material
Note: To access the supplementary material accom-
panying this article, visit the online version of Clinical
Gastroenterology and Hepatology at www.cghjournal.org,
and at http://dx.doi.org/10.1016/j.cgh.2017.06.007.
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ALAXY S3 14 (9%)
ALAXY S4 16 (11%)
ALAXY S5 16 (11%)
ALAXY S5 mini 2 (1%)
ALAXY S6 7 (5%)
ALAXY A3 0
ALAXY A5 0
ALAXY CORE PRIME LTE 0
NY
eria Z3 compact 1 (1%)
eria Z3 compact 1 (1%)
4 0
3 0






Variation in 10 readings of the
same test cassette
4% 6%
Variation in readings of 10 test cassettes loaded with one extract
Low-range calprotectin level (105 mg/g) 11% 4%
Middle-range calprotectin level (186 mg/g) 16% 11%
High-range calprotectin level (507 mg/g) 10% 16%
Variation in readings of 10 test cassettes loaded with 10 different
extracts
Low-range calprotectin level (105 mg/g) 17% 23%
Middle-range calprotectin level (186 mg/g) 18% 19%
High-range calprotectin level (507 mg/g) 25% 10%Supplementary Methods and Results:
Quality assessment
Method:We prepared three homogenized stool pools
representing a low, middle and high range calprotectin
level (respectively 105mg/g, 186mg/g, and 507mg/g). We
then prepared low, middle and high range CALEX
extraction ﬂuids. Thereafter, we performed 10 readings
of the same test cassette at one level, readings of 10 test
cassettes loaded with one extract (from the 3 pools), and
readings of 10 test cassettes loaded with 10 different
extracts (from the 3 pools).
Results: Sample reproducibility results of both IBDoc
and Quantum Blue are presented in the table below:
Supplementary Table 3. Concordance Between IBDoc and ELISA Calprotectin Result for Frequently Used Dichotomous
Cutoff Values
Concordant þ
(IBDoc [; ELISA [)
Concordant -
(IBDoc Y; ELISA Y)
Discordant
(IBDoc Y; ELISA [)
Discordant
(IBDoc [; ELISA Y)
Cutoff 50 mg/g 90 (59%) 45 (30%) 8 (5%) 9 (6%)
Cutoff 100 mg/g 69 (45%) 63 (41%) 10 (7%) 10 (7%)
Cutoff 150 mg/g 61 (40%) 74 (49%) 9 (6%) 8 (5%)
Cutoff 200 mg/g 50 (33%) 84 (55%) 8 (5%) 10 (7%)
Cutoff 250 mg/g 41 (27%) 91 (60%) 9 (6%) 11 (7%)
Cutoff 300 mg/g 34 (22%) 102 (67%) 8 (5%) 8 (5%)
Supplementary Figure 1.Overview of transport time.
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